BRAF and melanoma: The aim of this experimental study was to close this gap of knowledge, evaluating a novel BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human BRAF-V600-mutant melanoma using a multimodal imaging protocol of 18F–FDG-PET/CT and DW-MRI.